An exclusive license to a patent from Stanford University and the Chan Zuckerberg Biohub San Francisco has been secured by BioSkryb Genomics By connecting genetic changes with epigenetic states in the same cell, it provides greater context for making translational decisions, such as therapy selection. This approach is particularly useful for scarce samples, such as those from fine-needle aspirates.

BioSkryb's CEO, Suresh Pisharody, stated that the license addresses the customer need for detailed insights into both methylation and variants from the same cell without compromising sample integrity. Dr. Charles Gawad, BioSkryb's Founder and CSO, noted that this combined analysis moves single-cell biology from partial snapshots to a more complete picture, accelerating discovery and precision medicine.

Looking ahead, BioSkryb plans to develop a modular product that will allow for the analysis of genomic variants, methylation, the transcriptome, and the surface proteome from the same cell. The company is also investing in AI and machine learning to help interpret the complex multi-omic data and identify novel biomarker candidates. The goal is to provide wider access to this combined analysis to support researchers and, ultimately, patients.